On Monday, Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) opened higher 4.42% from the last session, before settling in for the closing price of $34.42. Price fluctuations for CRNX have ranged from $31.84 to $62.53 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 50.01%. Company’s average yearly earnings per share was noted -9.52% at the time writing. With a float of $86.59 million, this company’s outstanding shares have now reached $92.93 million.
Let’s determine the extent of company efficiency that accounts for 437 employees. In terms of profitability, gross margin is -18.09%, operating margin of -32675.07%, and the pretax margin is -28720.69%.
Crinetics Pharmaceuticals Inc (CRNX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Crinetics Pharmaceuticals Inc is 6.94%, while institutional ownership is 104.19%. The most recent insider transaction that took place on Mar 19 ’25, was worth 86,021. In this transaction Chief Med and Dev Officer of this company sold 2,515 shares at a rate of $34.20, taking the stock ownership to the 72,233 shares. Before that another transaction happened on Mar 19 ’25, when Company’s Chief Operating Officer sold 7,162 for $34.20, making the entire transaction worth $244,964. This insider now owns 87,491 shares in total.
Crinetics Pharmaceuticals Inc (CRNX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.52% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.31% during the next five years compared to -12.11% drop over the previous five years of trading.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Trading Performance Indicators
Check out the current performance indicators for Crinetics Pharmaceuticals Inc (CRNX). In the past quarter, the stock posted a quick ratio of 23.04.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.70, a number that is poised to hit -0.93 in the next quarter and is forecasted to reach -4.29 in one year’s time.
Technical Analysis of Crinetics Pharmaceuticals Inc (CRNX)
Looking closely at Crinetics Pharmaceuticals Inc (NASDAQ: CRNX), its last 5-days average volume was 1.09 million, which is a jump from its year-to-date volume of 1.02 million. As of the previous 9 days, the stock’s Stochastic %D was 63.05%. Additionally, its Average True Range was 1.60.
During the past 100 days, Crinetics Pharmaceuticals Inc’s (CRNX) raw stochastic average was set at 13.36%, which indicates a significant decrease from 95.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 32.16% in the past 14 days, which was lower than the 53.85% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $36.30, while its 200-day Moving Average is $48.58. However, in the short run, Crinetics Pharmaceuticals Inc’s stock first resistance to watch stands at $36.56. Second resistance stands at $37.17. The third major resistance level sits at $38.24. If the price goes on to break the first support level at $34.88, it is likely to go to the next support level at $33.81. Now, if the price goes above the second support level, the third support stands at $33.20.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Key Stats
There are currently 93,049K shares outstanding in the company with a market cap of 3.34 billion. Presently, the company’s annual sales total 1,040 K according to its annual income of -298,410 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -76,830 K.
